Knowledge, management, and complications of sepsis and septic shock: A significant therapeutic challenge in the intensive care unit

Abstract

Sepsis and septic shock are life-threatening conditions that are globally responsible for almost 20% of mortality, especially in low and middle-income countries. This review was conducted on PubMed and Google Scholar databases with keywords sepsis, septic shock, sepsis management, and sepsis complications. Articles published up to July 2023 in English were included. Diagnosis and management should be carried out without unnecessary delay. Cooperation between various medical specialties including intensive care doctors, neurologists, hepatologists, cardiologists, and pediatric doctors is needed if a child is affected. New strategies have to be implemented in low and middle-income countries to decrease the sepsis incidence and reduce mortality in the population.

Keywords

Sepsis / Septic shock / Management / Complications / Diagnosis / Review

References

[1] Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, et al. Global, regional, and national sepsis incidence and mortality, 1990—2017: Analysis for the Global Burden of Disease Study. Lancet 2020; 395(10219): 200-211. DOI: 10.1016/S0140-6736(19)32989-7.

[2] Rello J, Valenzuela—Sánchez F, Ruiz—Rodriguez M, Moyano S. Sepsis: A review of advances in management. Adv Ther 2017; 34: 2393. DOI: 10.1007/S12325-017-0622-8.

[3] Dolin HH, Papadimos TJ, Chen X, Pan ZK. Characterization of pathogenic sepsis etiologies and patient: A novel approach to triage and treatment. Microbiol Insights 2019; 12: 117863611882508. DOI: 10.1177/1178636118825081.

[4] Mayr FB, Yende S, Angus DC. Epidemiology of severe sepsis. Virulence 2014; 5: 4. DOI: 10.4161/VIRU.27372.

[5] Palavutitotai N, Jitmuang A, Tongsai S, Kiratisin P, Angkasekwinai N. Epidemiology and risk factors of extensively drug—resistant Pseudomonas aeruginosa infections. PLoS One 2018; 13. DOI: 10.1371/JOURNAL.PONE.0193431.

[6] Thaden JT, Li Y, Ruffin F, Maskarinec SA, Hill—Rorie JM, Wanda LC, et al. Increased costs associated with bloodstream infections caused by multidrug—resistant gram—negative bacteria are due primarily to patients with hospital—acquired infections. Antimicrob Agents Chemother 2017; 61. DOI: 10.1128/AAC.01709-16.

[7] Koch RM, Kox M, De Jonge MI, Van Der Hoeven JG, Ferwerda G, Pickkers P. Patterns in bacterial— and viral—induced immunosuppression and secondary infections in the ICU. Shock 2017; 47: 5-12. DOI: 10.1097/SHK.0000000000000731.

[8] Caballero MT, Polack FP. Respiratory syncytial virus is an “opportunistic” killer. Pediatr Pulmonol 2018; 53: 664-667. DOI: 10.1002/PPUL.23963.

[9] Singer M, Deutschman CS, Seymour C, Shankar—Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (Sepsis—3). JAMA 2016; 315: 801. DOI: 10.1001/JAMA.2016.0287.

[10] Salomão R, Ferreira BL, Salomão MC, Santos SS, Azevedo LC, Brunialti MK. Sepsis: Evolving concepts and challenges. Brazilian J Med Biol Res 2019; 52. DOI: 10.1590/1414-431X20198595.

[11] Machado FR, De Assunção MSC, Cavalcanti AB, Japiassú AM, De Azevedo LC, Oliveira MC. Getting a consensus: Advantages and disadvantages of sepsis 3 in the context of middle—income settings. Rev Bras Ter Intensiva 2016; 28: 361. DOI: 10.5935/0103-507X.20160068.

[12] Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101: 1644-1655. DOI: 10.1378/CHEST.101.6.1644.

[13] Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003; 31: 1250-1256. DOI: 10.1097/01.CCM.0000050454.01978.3B.

[14] Dellinger RP, Levy M, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013; 41: 580-637. DOI: 10.1097/CCM.0B013E31827E83AF.

[15] Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez—Rodriguez A, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709. DOI: 10.1056/NEJM200103083441001.

[16] Shankar—Hari M, Phillips GS, Levy ML, Seymour CW, Liu VX, Deutschman CS, et al. Developing a new definition and assessing new clinical criteria for septic shock: For the third international consensus definitions for sepsis and septic shock (Sepsis—3). JAMA 2016; 315: 775. DOI: 10.1001/JAMA.2016.0289.

[17] Gavelli F, Castello LM, Avanzi GC. Management of sepsis and septic shock in the emergency department. Intern Emerg Med 2021; 16: 1649. DOI: 10.1007/S11739-021-02735-7.

[18] Levy MM, Evans LE, Rhodes A. The surviving sepsis campaign bundle: 2018 Update. Crit Care Med 2018; 46: 997-1000. DOI: 10.1097/CCM.0000000000003119.

[19] Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34: 1589-1596. DOI: 10.1097/01.CCM.0000217961.75225.E9.

[20] Funk DJ, Kumar A. Antimicrobial therapy for life—threatening infections: Speed is life. Crit Care Clin 2011; 27: 53-76. DOI: 10.1016/J.CCC.2010.09.008.

[21] Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving sepsis campaign: International guidelines for management of sepsis and septic shock: 2016. Crit Care Med 2017; 45: 486-552. DOI: 10.1097/CCM.0000000000002255.

[22] Kalil AC, Gilbert DN, Winslow DL, Masur H, Klompas M. Infectious Diseases Society of America (IDSA) Position Statement: Why IDSA did not endorse the surviving sepsis campaign guidelines. Clin Infect Dis 2018; 66: 1631. DOI: 10.1093/CID/CIX997.

[23] Pappas PG, Kauffman CA, Andes D, Benjamin DK, Calandra TF, Edwards JE, et al. Clinical practice guidelines for the management of candidiasis: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503. DOI: 10.1086/596757.

[24] Rochwerg B, Alhazzani W, Sindi A, Heels—Ansdell D, Thabane L, Fox—Robichaud A, et al. Fluid resuscitation in sepsis: A systematic review and network meta—analysis. Ann Intern Med 2014; 161: 347-355. DOI: 10.7326/M14-0178.

[25] Monnet X, Teboul JL. Prediction of fluid responsiveness in spontaneously breathing patients. Ann Transl Med 2020; 8: 790— 790. DOI: 10.21037/ATM-2020-HDM-18.

[26] Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C. et al. Surviving sepsis campaign: International guidelines for management of sepsis and septic shock 2021. Crit Care Med 2021; 49: E1063-E1143. DOI: 10.1097/CCM.0000000000005337.

[27] De Backer D, Creteur J, Silva E, Vincent JL. Effects of dopamine, norepinephrine, and epinephrine on the splanchnic circulation in septic shock: Which is best? Crit Care Med 2003; 31: 1659-1667. DOI: 10.1097/01.CCM.0000063045.77339.B6.

[28] Marik PE, Khangoora V, Rivera R, Hooper MH, Catravas J. Hydrocortisone, vitamin C, and thiamine for the treatment of severe sepsis and septic shock: A retrospective before—after study. Chest 2017; 151: 1229-1238. DOI: 10.1016/J.CHEST.2016.11.036.

[29] Moskowitz A, Andersen LW, Huang DT, Berg KM, Grossestreuer AV, Marik PE, et al. Ascorbic acid, corticosteroids, and thiamine in sepsis: A review of the biologic rationale and the present state of clinical evaluation. Crit Care 2018; 22. DOI: 10.1186/S13054-018-2217-4.

[30] Woznica EA, Inglot M, Woznica RK, Lysenko L. Liver dysfunction in sepsis. Adv Clin Exp Med 2018; 27: 547-551. DOI: 10.17219/ACEM/68363.

[31] Chand N, Sanyal AJ. Sepsis—induced cholestasis. Hepatology 2007; 45: 230-241. DOI: 10.1002/HEP.21480.

[32] Kobashi H, Toshimori J, Yamamoto K. Sepsis—associated liver injury: Incidence, classification and the clinical significance. Hepatol Res 2013; 43: 255-266. DOI: 10.1111/J.1872-034X.2012.01069.X.

[33] Taylor J, Toh CH, Hoots WK, Wada H, Levi M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation: On behalf of the scientific subcommittee on disseminated intravascular coagulation (DIC) of the International Society on Thrombosis and Haematostasis (ISTH). Thromb Haemost 2001; 86: 1327-1330. DOI: 10.1055/S-0037-1616068/BIB.

[34] Iba T, Levi M, Levy JH. Sepsis—induced coagulopathy and disseminated intravascular coagulation. Semin Thromb Hemost 2020; 46: 89-95. DOI: 10.1055/S-0039-1694995.

[35] Dimopoulou I, Tsagarakis S, Kouyialis AT, Roussou P, Assithianakis G, Christoforaki M, et al. Hypothalamic—pituitary—adrenal axis dysfunction in critically ill patients with traumatic brain injury: Incidence, pathophysiology, and relationship to vasopressor dependence and peripheral interleukin—6 levels. Crit Care Med 2004; 32: 404-408. DOI: 10.1097/01.CCM.0000108885.37811.CA.

[36] Ren C, Yao RQ, Zhang H, Feng YW, Yao YM. Sepsis—associated encephalopathy: A vicious cycle of immunosuppression. J Neuroinflammation 2020; 17. DOI: 10.1186/S12974-020-1701-3.

[37] Levy RJ, Deutschman CS. Evaluating myocardial depression in sepsis. Shock 2004; 22: 1-10. DOI: 10.1097/01.SHK.0000129198.53836.15.

[38] Flynn A, Chokkalingam Mani B, Mather PJ. Sepsis—induced cardiomyopathy: A review of pathophysiologic mechanisms. Heart Fail Rev 2010; 15: 605-611. DOI: 10.1007/S10741-010-9176-4.

[39] Hollenberg SM, Singer M. Pathophysiology of sepsis—induced cardiomyopathy. Nat Rev Cardiol 2021; 18: 424-434. DOI: 10.1038/S41569-020-00492-2.